# NeoTRIP (NCT02620280)

> Neoadjuvant Therapy in TRIPle Negative Breast Cancer With antiPDL1

No report yet. It can be ordered.

- Drugs tested: atezolizumab
- Indication: early high-risk and locally advanced triple-negative breast cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02620280
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Fondazione Michelangelo
- Conditions: Invasive Ductal Breast Carcinoma
- Interventions: Carboplatin; Abraxane; MPDL3280A; Surgery; Anthra
- Enrollment: 278
- Primary outcome: Event Free Survival (EFS)

## Questions raised in the commentary

_Automated from the 40 newest of 190 indexed sources (Jun 2023 – Oct 2026). Each question is raised in at least two. Not an Erudio report: no source links. Not medical advice._

- What explains differences in atezolizumab outcomes across early TNBC studies
- Whether anthracyclines are needed alongside immunotherapy
- How confidently to interpret the immunotherapy findings

Also discussed: transcriptomic response biomarkers, CD204+ macrophages.

## Indexed commentary on NeoTRIP so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 145 posts on X
- 32 YouTube videos
- 9 podcast episodes
- 3 posts on Bluesky
- 1 video on X

## Order

Deep, $1,950 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=neotrip-nct02620280

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02620280", "email": "<work email>"}; the inbox owner confirms by the emailed link.